Syncom Formulations (India) Ltd is a Stage 1 pharma company specializing in API and formulation manufacturing for global and domestic markets. Its core business includes bulk drug production and finished dosage forms, targeting chronic disease segments. Growth will hinge on scaling existing contracts, cost optimization in a competitive industry, and potential expansion into high-margin generics. Over 2-3 years, the company could benefit from India’s growing role as a global API hub, though execution risks include margin pressures from raw material volatility. Key execution risks involve maintaining quality compliance and securing long-term client partnerships to sustain revenue visibility.
companyname: SYNCOM FORMULATIONS (INDIA) LIMITED ticker: SYNCOMF sector: Pharmaceuticals Syncom Formulations (India) Limited is a pharmaceutical company that manufactures and sells medicines across domestic and international markets. The company operates from a manufacturing plant in Pithampur, Madhya Pradesh, with a corporate office in Indore and a registered office in Mumbai. Its product range spans tablets, capsules, injectables, sprays, ointments, creams and liquids. The annual report descr...
Read the full report →Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Syncom Formulations (India) Limited and 4,900+ companies.
5-day free pass. No card required.